CookInSuit personal page - To The Moon

CookInSuit

CookInSuit

No personal profile

10Follow

0Followers

0Topic

0Badge

2021-07-22

China still has a lot of room to end higher. Hopefully Q3 to bring further growth

China shares end higher, foreign investors extend buying

2021-06-23

Tesla has the halo effect. Wonder when Elon will wear out his halo..

3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes

2021-06-23

How is the recovery trade over when there the world is still going through second and third wavesof Covid?

Barclays chief stock strategist says Covid recovery trade is over, go back into Big Tech

2021-06-23

More importantly, how did they get there? Equity investment? Property investment?

Singapore’s Millionaires Count Expected to Surge 62% by 2025

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582529687850113","uuid":"3582529687850113","gmtCreate":1619440321763,"gmtModify":1624417532385,"name":"CookInSuit","pinyin":"cookinsuit","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/1a79bf61194a552988070fe312f320ed","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":10,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.63%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":172844349,"gmtCreate":1626955282781,"gmtModify":1703481253875,"author":{"id":"3582529687850113","authorId":"3582529687850113","name":"CookInSuit","avatar":"https://static.tigerbbs.com/1a79bf61194a552988070fe312f320ed","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582529687850113","authorIdStr":"3582529687850113"},"themes":[],"htmlText":"China still has a lot of room to end higher. Hopefully Q3 to bring further growth","listText":"China still has a lot of room to end higher. Hopefully Q3 to bring further growth","text":"China still has a lot of room to end higher. Hopefully Q3 to bring further growth","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172844349","repostId":"1161032014","repostType":4,"repost":{"id":"1161032014","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626940565,"share":"https://ttm.financial/m/news/1161032014?lang=&edition=fundamental","pubTime":"2021-07-22 15:56","market":"hk","language":"en","title":"China shares end higher, foreign investors extend buying","url":"https://stock-news.laohu8.com/highlight/detail?id=1161032014","media":"Reuters","summary":"Shanghai stocks higher, blue-chip CSI300 index up\n\n\nGains in Shanghai stocks led by Sichuan Hebang B","content":"<ul>\n <li>Shanghai stocks higher, blue-chip CSI300 index up</li>\n</ul>\n<ul>\n <li>Gains in Shanghai stocks led by Sichuan Hebang Biotechnology Co Ltd and losses by Cangzhou Dahua Co Ltd. China’s A-shares are at a 39.14% premium over H-shares.</li>\n</ul>\n<p>SHANGHAI, July 22 (Reuters) - China shares rose on Thursday as gains in financials and materials firms outweighed losses in healthcare stocks, and as foreign investors extended net buying of A-shares through the Stock Connect scheme into a fourth consecutive day.</p>\n<ul>\n <li>At the close, the Shanghai Composite index was up 0.34% at 3,574.73.</li>\n <li>The blue-chip CSI300 index was up 0.15%, with its financial sector sub-index higher 1.12%, the CSI all share materials gaining 2.35% and the real estate index up 1.38%.</li>\n <li>The healthcare sub-index slumped 3.64% after three days of strong gains.</li>\n <li>Sentiment in the property sector was boosted after developer China Evergrande Group said it had solved legal disputes with China Guangfa Bank and that the two sides would deepen business cooperation, easing investor concerns that sparked a three-day sell-off.</li>\n <li>Refinitiv data showed foreign investors were net buyers of A-shares through the Northbound leg of the Stock Connect programme , the fourth straight day of net purchases.</li>\n <li>The smaller Shenzhen index ended up 0.45% and the start-up board ChiNext Composite index was weaker by 0.438%.</li>\n <li>Around the region, MSCI’s Asia ex-Japan stock index was firmer by 1.21%, while Japan’s Nikkei index ended up 0.58%. ** At 07:22, the yuan was quoted at 6.4652 per U.S. dollar, 0.05% firmer than the previous close of 6.4685.</li>\n <li>So far this year, the Shanghai stock index is up 2.9% and the CSI300 has fallen 1.1%, while China’s H-share index listed in Hong Kong is down 7%. Shanghai stocks have declined 0.46% this month.</li>\n</ul>\n<p>(Reporting by Shanghai Newsroom; editing by Vinay Dwivedi)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China shares end higher, foreign investors extend buying</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina shares end higher, foreign investors extend buying\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-22 15:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Shanghai stocks higher, blue-chip CSI300 index up</li>\n</ul>\n<ul>\n <li>Gains in Shanghai stocks led by Sichuan Hebang Biotechnology Co Ltd and losses by Cangzhou Dahua Co Ltd. China’s A-shares are at a 39.14% premium over H-shares.</li>\n</ul>\n<p>SHANGHAI, July 22 (Reuters) - China shares rose on Thursday as gains in financials and materials firms outweighed losses in healthcare stocks, and as foreign investors extended net buying of A-shares through the Stock Connect scheme into a fourth consecutive day.</p>\n<ul>\n <li>At the close, the Shanghai Composite index was up 0.34% at 3,574.73.</li>\n <li>The blue-chip CSI300 index was up 0.15%, with its financial sector sub-index higher 1.12%, the CSI all share materials gaining 2.35% and the real estate index up 1.38%.</li>\n <li>The healthcare sub-index slumped 3.64% after three days of strong gains.</li>\n <li>Sentiment in the property sector was boosted after developer China Evergrande Group said it had solved legal disputes with China Guangfa Bank and that the two sides would deepen business cooperation, easing investor concerns that sparked a three-day sell-off.</li>\n <li>Refinitiv data showed foreign investors were net buyers of A-shares through the Northbound leg of the Stock Connect programme , the fourth straight day of net purchases.</li>\n <li>The smaller Shenzhen index ended up 0.45% and the start-up board ChiNext Composite index was weaker by 0.438%.</li>\n <li>Around the region, MSCI’s Asia ex-Japan stock index was firmer by 1.21%, while Japan’s Nikkei index ended up 0.58%. ** At 07:22, the yuan was quoted at 6.4652 per U.S. dollar, 0.05% firmer than the previous close of 6.4685.</li>\n <li>So far this year, the Shanghai stock index is up 2.9% and the CSI300 has fallen 1.1%, while China’s H-share index listed in Hong Kong is down 7%. Shanghai stocks have declined 0.46% this month.</li>\n</ul>\n<p>(Reporting by Shanghai Newsroom; editing by Vinay Dwivedi)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"399006":"创业板指","603077":"和邦生物","002236":"大华股份","000300.SH":"沪深300"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161032014","content_text":"Shanghai stocks higher, blue-chip CSI300 index up\n\n\nGains in Shanghai stocks led by Sichuan Hebang Biotechnology Co Ltd and losses by Cangzhou Dahua Co Ltd. China’s A-shares are at a 39.14% premium over H-shares.\n\nSHANGHAI, July 22 (Reuters) - China shares rose on Thursday as gains in financials and materials firms outweighed losses in healthcare stocks, and as foreign investors extended net buying of A-shares through the Stock Connect scheme into a fourth consecutive day.\n\nAt the close, the Shanghai Composite index was up 0.34% at 3,574.73.\nThe blue-chip CSI300 index was up 0.15%, with its financial sector sub-index higher 1.12%, the CSI all share materials gaining 2.35% and the real estate index up 1.38%.\nThe healthcare sub-index slumped 3.64% after three days of strong gains.\nSentiment in the property sector was boosted after developer China Evergrande Group said it had solved legal disputes with China Guangfa Bank and that the two sides would deepen business cooperation, easing investor concerns that sparked a three-day sell-off.\nRefinitiv data showed foreign investors were net buyers of A-shares through the Northbound leg of the Stock Connect programme , the fourth straight day of net purchases.\nThe smaller Shenzhen index ended up 0.45% and the start-up board ChiNext Composite index was weaker by 0.438%.\nAround the region, MSCI’s Asia ex-Japan stock index was firmer by 1.21%, while Japan’s Nikkei index ended up 0.58%. ** At 07:22, the yuan was quoted at 6.4652 per U.S. dollar, 0.05% firmer than the previous close of 6.4685.\nSo far this year, the Shanghai stock index is up 2.9% and the CSI300 has fallen 1.1%, while China’s H-share index listed in Hong Kong is down 7%. Shanghai stocks have declined 0.46% this month.\n\n(Reporting by Shanghai Newsroom; editing by Vinay Dwivedi)","news_type":1},"isVote":1,"tweetType":1,"viewCount":381,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123122244,"gmtCreate":1624412935588,"gmtModify":1703835894164,"author":{"id":"3582529687850113","authorId":"3582529687850113","name":"CookInSuit","avatar":"https://static.tigerbbs.com/1a79bf61194a552988070fe312f320ed","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582529687850113","authorIdStr":"3582529687850113"},"themes":[],"htmlText":"Tesla has the halo effect. Wonder when Elon will wear out his halo..","listText":"Tesla has the halo effect. Wonder when Elon will wear out his halo..","text":"Tesla has the halo effect. Wonder when Elon will wear out his halo..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123122244","repostId":"2145599620","repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNOW":"Snowflake","TSLA":"特斯拉","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123129616,"gmtCreate":1624412720935,"gmtModify":1703835886825,"author":{"id":"3582529687850113","authorId":"3582529687850113","name":"CookInSuit","avatar":"https://static.tigerbbs.com/1a79bf61194a552988070fe312f320ed","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582529687850113","authorIdStr":"3582529687850113"},"themes":[],"htmlText":"How is the recovery trade over when there the world is still going through second and third&nbsp;wavesof Covid?","listText":"How is the recovery trade over when there the world is still going through second and third&nbsp;wavesof Covid?","text":"How is the recovery trade over when there the world is still going through second and third wavesof Covid?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123129616","repostId":"1168688117","repostType":4,"repost":{"id":"1168688117","pubTimestamp":1624404535,"share":"https://ttm.financial/m/news/1168688117?lang=&edition=fundamental","pubTime":"2021-06-23 07:28","market":"us","language":"en","title":"Barclays chief stock strategist says Covid recovery trade is over, go back into Big Tech","url":"https://stock-news.laohu8.com/highlight/detail?id=1168688117","media":"CNBC","summary":"The pandemic recovery trade has run its course, and now it’s time to get back into Big Tech stocks, ","content":"<div>\n<p>The pandemic recovery trade has run its course, and now it’s time to get back into Big Tech stocks, one market strategist told clients Tuesday.\n“We believe market leadership is likely to change from ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/22/stocks-barclays-strategist-says-go-back-into-big-tech.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Barclays chief stock strategist says Covid recovery trade is over, go back into Big Tech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBarclays chief stock strategist says Covid recovery trade is over, go back into Big Tech\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 07:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/22/stocks-barclays-strategist-says-go-back-into-big-tech.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pandemic recovery trade has run its course, and now it’s time to get back into Big Tech stocks, one market strategist told clients Tuesday.\n“We believe market leadership is likely to change from ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/22/stocks-barclays-strategist-says-go-back-into-big-tech.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞","AAPL":"苹果","AMZN":"亚马逊","GOOG":"谷歌","MSFT":"微软"},"source_url":"https://www.cnbc.com/2021/06/22/stocks-barclays-strategist-says-go-back-into-big-tech.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1168688117","content_text":"The pandemic recovery trade has run its course, and now it’s time to get back into Big Tech stocks, one market strategist told clients Tuesday.\n“We believe market leadership is likely to change from cyclical to secular growth stocks as the Covid recovery trade has mostly run its course. Secular growth stocks look favorably positioned to benefit from the digital transformation that got accelerated during Covid,” Barclays head of U.S. equity strategy Maneesh Deshpandesaid in a note.\nValue and cyclical stocks shone in 2021, as investors turned to names that perform well in a recovering economy. But the growth theme is back in vogue as investors worry that much of the pandemic rebound has already been priced into those recovery names.\n“Following positive news on the vaccine front in November 2020, as the path to a cyclical economic recovery in 2021 became clearer, there was a rotation that began away from stocks with positive exposure to COVID-19 and into stocks with negative exposure to it,” Deshpande said. “We think this rotation is now complete.”\nGrowth stocks are shares of companies that are expected to grow at a faster rate than the rest of the market. In particular, secular growth stocks follow a longer-term trend and are less influenced by the overall economy.\nAccording to Barclays, technology names are particularly well-positioned for the moment due to an acceleration of digital transformation during the pandemic. Tech stocks stand to benefit from the growth of e-commerce marketplaces, digital advertising, work-from-home technology and cloud infrastructure, the bank said.\nBarclays is bullish on FANMAG stocks — a group of mega-cap tech names including Facebook,Amazon,Netflix,Microsoft,Appleand Google-parentAlphabet. What’s more, the bank believes these Big Tech names are relatively cheap now after lagging earlier this year.\n“We prefer FANMAGs as their valuations have declined to 2019 [year-end] levels,” Deshpande said.\nMeanwhile, Barclays believes software stock valuations are currently expensive, so it prefers to stick with FANMAGs.\nOut of the tech giant names, Barclays likes Alphabet, Microsoft and Amazon in particular, as the bank expects these stocks to “hold on to their Covid market share gains and continue to benefit from the acceleration of digital transformation.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123162053,"gmtCreate":1624412532872,"gmtModify":1703835879136,"author":{"id":"3582529687850113","authorId":"3582529687850113","name":"CookInSuit","avatar":"https://static.tigerbbs.com/1a79bf61194a552988070fe312f320ed","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582529687850113","authorIdStr":"3582529687850113"},"themes":[],"htmlText":"More importantly, how did they get there? Equity investment? Property investment?","listText":"More importantly, how did they get there? Equity investment? Property investment?","text":"More importantly, how did they get there? Equity investment? Property investment?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/123162053","repostId":"1139503540","repostType":4,"repost":{"id":"1139503540","pubTimestamp":1624410306,"share":"https://ttm.financial/m/news/1139503540?lang=&edition=fundamental","pubTime":"2021-06-23 09:05","market":"sg","language":"en","title":"Singapore’s Millionaires Count Expected to Surge 62% by 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1139503540","media":"Bloomberg","summary":"Singapore’s count of millionaires could increase by more than 60% over the five years from 2020 to 2","content":"<p>Singapore’s count of millionaires could increase by more than 60% over the five years from 2020 to 2025, according toCredit Suisse Group AG, part of a surge in millionaires expected in Asia as financial capitals emerge from the Covid-19 pandemic.</p>\n<p>The city-state may have 437,000 millionaires by 2025 compared with 270,000 in 2020, according to the bank’s2021 Global Wealth Report. That 62% pace would be faster than Hong Kong’s estimated 60% for the same period, but slower than the growth forecast in mainland China, India, Australia, South Korea and Tawian.</p>\n<p>Singapore’s millionaire density -- or percentage of millionaires in the total population -- was 5.5% in 2020, the second-highest in Asia after Hong Kong’s 8.3%, the report said. The island nation’s Gini coefficient -- a more broad-based measure of wealth inequality -- was at 78.3 in 2020, much higher than Japan’s 64.4, South Korea’s 67.6 and Taiwan’s 70.8.</p>\n<p>The wealth share of the top 1% in Singapore was almost 34% at the end of 2020, compared with 18% for Japan, 24% for South Korea and 28% for Taiwan. In a small country like Singapore, higher wealth inequality can result from an unrepresentative cluster of very high net-worth individuals, the report said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore’s Millionaires Count Expected to Surge 62% by 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore’s Millionaires Count Expected to Surge 62% by 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 09:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-23/singapore-s-millionaires-count-expected-to-surge-62-by-2025><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Singapore’s count of millionaires could increase by more than 60% over the five years from 2020 to 2025, according toCredit Suisse Group AG, part of a surge in millionaires expected in Asia as ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-23/singapore-s-millionaires-count-expected-to-surge-62-by-2025\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-23/singapore-s-millionaires-count-expected-to-surge-62-by-2025","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139503540","content_text":"Singapore’s count of millionaires could increase by more than 60% over the five years from 2020 to 2025, according toCredit Suisse Group AG, part of a surge in millionaires expected in Asia as financial capitals emerge from the Covid-19 pandemic.\nThe city-state may have 437,000 millionaires by 2025 compared with 270,000 in 2020, according to the bank’s2021 Global Wealth Report. That 62% pace would be faster than Hong Kong’s estimated 60% for the same period, but slower than the growth forecast in mainland China, India, Australia, South Korea and Tawian.\nSingapore’s millionaire density -- or percentage of millionaires in the total population -- was 5.5% in 2020, the second-highest in Asia after Hong Kong’s 8.3%, the report said. The island nation’s Gini coefficient -- a more broad-based measure of wealth inequality -- was at 78.3 in 2020, much higher than Japan’s 64.4, South Korea’s 67.6 and Taiwan’s 70.8.\nThe wealth share of the top 1% in Singapore was almost 34% at the end of 2020, compared with 18% for Japan, 24% for South Korea and 28% for Taiwan. In a small country like Singapore, higher wealth inequality can result from an unrepresentative cluster of very high net-worth individuals, the report said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":123162053,"gmtCreate":1624412532872,"gmtModify":1703835879136,"author":{"id":"3582529687850113","authorId":"3582529687850113","name":"CookInSuit","avatar":"https://static.tigerbbs.com/1a79bf61194a552988070fe312f320ed","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582529687850113","authorIdStr":"3582529687850113"},"themes":[],"htmlText":"More importantly, how did they get there? Equity investment? Property investment?","listText":"More importantly, how did they get there? Equity investment? Property investment?","text":"More importantly, how did they get there? Equity investment? Property investment?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/123162053","repostId":"1139503540","repostType":4,"repost":{"id":"1139503540","pubTimestamp":1624410306,"share":"https://ttm.financial/m/news/1139503540?lang=&edition=fundamental","pubTime":"2021-06-23 09:05","market":"sg","language":"en","title":"Singapore’s Millionaires Count Expected to Surge 62% by 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1139503540","media":"Bloomberg","summary":"Singapore’s count of millionaires could increase by more than 60% over the five years from 2020 to 2","content":"<p>Singapore’s count of millionaires could increase by more than 60% over the five years from 2020 to 2025, according toCredit Suisse Group AG, part of a surge in millionaires expected in Asia as financial capitals emerge from the Covid-19 pandemic.</p>\n<p>The city-state may have 437,000 millionaires by 2025 compared with 270,000 in 2020, according to the bank’s2021 Global Wealth Report. That 62% pace would be faster than Hong Kong’s estimated 60% for the same period, but slower than the growth forecast in mainland China, India, Australia, South Korea and Tawian.</p>\n<p>Singapore’s millionaire density -- or percentage of millionaires in the total population -- was 5.5% in 2020, the second-highest in Asia after Hong Kong’s 8.3%, the report said. The island nation’s Gini coefficient -- a more broad-based measure of wealth inequality -- was at 78.3 in 2020, much higher than Japan’s 64.4, South Korea’s 67.6 and Taiwan’s 70.8.</p>\n<p>The wealth share of the top 1% in Singapore was almost 34% at the end of 2020, compared with 18% for Japan, 24% for South Korea and 28% for Taiwan. In a small country like Singapore, higher wealth inequality can result from an unrepresentative cluster of very high net-worth individuals, the report said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore’s Millionaires Count Expected to Surge 62% by 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore’s Millionaires Count Expected to Surge 62% by 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 09:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-23/singapore-s-millionaires-count-expected-to-surge-62-by-2025><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Singapore’s count of millionaires could increase by more than 60% over the five years from 2020 to 2025, according toCredit Suisse Group AG, part of a surge in millionaires expected in Asia as ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-23/singapore-s-millionaires-count-expected-to-surge-62-by-2025\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-23/singapore-s-millionaires-count-expected-to-surge-62-by-2025","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139503540","content_text":"Singapore’s count of millionaires could increase by more than 60% over the five years from 2020 to 2025, according toCredit Suisse Group AG, part of a surge in millionaires expected in Asia as financial capitals emerge from the Covid-19 pandemic.\nThe city-state may have 437,000 millionaires by 2025 compared with 270,000 in 2020, according to the bank’s2021 Global Wealth Report. That 62% pace would be faster than Hong Kong’s estimated 60% for the same period, but slower than the growth forecast in mainland China, India, Australia, South Korea and Tawian.\nSingapore’s millionaire density -- or percentage of millionaires in the total population -- was 5.5% in 2020, the second-highest in Asia after Hong Kong’s 8.3%, the report said. The island nation’s Gini coefficient -- a more broad-based measure of wealth inequality -- was at 78.3 in 2020, much higher than Japan’s 64.4, South Korea’s 67.6 and Taiwan’s 70.8.\nThe wealth share of the top 1% in Singapore was almost 34% at the end of 2020, compared with 18% for Japan, 24% for South Korea and 28% for Taiwan. In a small country like Singapore, higher wealth inequality can result from an unrepresentative cluster of very high net-worth individuals, the report said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172844349,"gmtCreate":1626955282781,"gmtModify":1703481253875,"author":{"id":"3582529687850113","authorId":"3582529687850113","name":"CookInSuit","avatar":"https://static.tigerbbs.com/1a79bf61194a552988070fe312f320ed","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582529687850113","authorIdStr":"3582529687850113"},"themes":[],"htmlText":"China still has a lot of room to end higher. Hopefully Q3 to bring further growth","listText":"China still has a lot of room to end higher. Hopefully Q3 to bring further growth","text":"China still has a lot of room to end higher. Hopefully Q3 to bring further growth","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/172844349","repostId":"1161032014","repostType":4,"repost":{"id":"1161032014","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626940565,"share":"https://ttm.financial/m/news/1161032014?lang=&edition=fundamental","pubTime":"2021-07-22 15:56","market":"hk","language":"en","title":"China shares end higher, foreign investors extend buying","url":"https://stock-news.laohu8.com/highlight/detail?id=1161032014","media":"Reuters","summary":"Shanghai stocks higher, blue-chip CSI300 index up\n\n\nGains in Shanghai stocks led by Sichuan Hebang B","content":"<ul>\n <li>Shanghai stocks higher, blue-chip CSI300 index up</li>\n</ul>\n<ul>\n <li>Gains in Shanghai stocks led by Sichuan Hebang Biotechnology Co Ltd and losses by Cangzhou Dahua Co Ltd. China’s A-shares are at a 39.14% premium over H-shares.</li>\n</ul>\n<p>SHANGHAI, July 22 (Reuters) - China shares rose on Thursday as gains in financials and materials firms outweighed losses in healthcare stocks, and as foreign investors extended net buying of A-shares through the Stock Connect scheme into a fourth consecutive day.</p>\n<ul>\n <li>At the close, the Shanghai Composite index was up 0.34% at 3,574.73.</li>\n <li>The blue-chip CSI300 index was up 0.15%, with its financial sector sub-index higher 1.12%, the CSI all share materials gaining 2.35% and the real estate index up 1.38%.</li>\n <li>The healthcare sub-index slumped 3.64% after three days of strong gains.</li>\n <li>Sentiment in the property sector was boosted after developer China Evergrande Group said it had solved legal disputes with China Guangfa Bank and that the two sides would deepen business cooperation, easing investor concerns that sparked a three-day sell-off.</li>\n <li>Refinitiv data showed foreign investors were net buyers of A-shares through the Northbound leg of the Stock Connect programme , the fourth straight day of net purchases.</li>\n <li>The smaller Shenzhen index ended up 0.45% and the start-up board ChiNext Composite index was weaker by 0.438%.</li>\n <li>Around the region, MSCI’s Asia ex-Japan stock index was firmer by 1.21%, while Japan’s Nikkei index ended up 0.58%. ** At 07:22, the yuan was quoted at 6.4652 per U.S. dollar, 0.05% firmer than the previous close of 6.4685.</li>\n <li>So far this year, the Shanghai stock index is up 2.9% and the CSI300 has fallen 1.1%, while China’s H-share index listed in Hong Kong is down 7%. Shanghai stocks have declined 0.46% this month.</li>\n</ul>\n<p>(Reporting by Shanghai Newsroom; editing by Vinay Dwivedi)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China shares end higher, foreign investors extend buying</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina shares end higher, foreign investors extend buying\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-22 15:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Shanghai stocks higher, blue-chip CSI300 index up</li>\n</ul>\n<ul>\n <li>Gains in Shanghai stocks led by Sichuan Hebang Biotechnology Co Ltd and losses by Cangzhou Dahua Co Ltd. China’s A-shares are at a 39.14% premium over H-shares.</li>\n</ul>\n<p>SHANGHAI, July 22 (Reuters) - China shares rose on Thursday as gains in financials and materials firms outweighed losses in healthcare stocks, and as foreign investors extended net buying of A-shares through the Stock Connect scheme into a fourth consecutive day.</p>\n<ul>\n <li>At the close, the Shanghai Composite index was up 0.34% at 3,574.73.</li>\n <li>The blue-chip CSI300 index was up 0.15%, with its financial sector sub-index higher 1.12%, the CSI all share materials gaining 2.35% and the real estate index up 1.38%.</li>\n <li>The healthcare sub-index slumped 3.64% after three days of strong gains.</li>\n <li>Sentiment in the property sector was boosted after developer China Evergrande Group said it had solved legal disputes with China Guangfa Bank and that the two sides would deepen business cooperation, easing investor concerns that sparked a three-day sell-off.</li>\n <li>Refinitiv data showed foreign investors were net buyers of A-shares through the Northbound leg of the Stock Connect programme , the fourth straight day of net purchases.</li>\n <li>The smaller Shenzhen index ended up 0.45% and the start-up board ChiNext Composite index was weaker by 0.438%.</li>\n <li>Around the region, MSCI’s Asia ex-Japan stock index was firmer by 1.21%, while Japan’s Nikkei index ended up 0.58%. ** At 07:22, the yuan was quoted at 6.4652 per U.S. dollar, 0.05% firmer than the previous close of 6.4685.</li>\n <li>So far this year, the Shanghai stock index is up 2.9% and the CSI300 has fallen 1.1%, while China’s H-share index listed in Hong Kong is down 7%. Shanghai stocks have declined 0.46% this month.</li>\n</ul>\n<p>(Reporting by Shanghai Newsroom; editing by Vinay Dwivedi)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"399006":"创业板指","603077":"和邦生物","002236":"大华股份","000300.SH":"沪深300"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161032014","content_text":"Shanghai stocks higher, blue-chip CSI300 index up\n\n\nGains in Shanghai stocks led by Sichuan Hebang Biotechnology Co Ltd and losses by Cangzhou Dahua Co Ltd. China’s A-shares are at a 39.14% premium over H-shares.\n\nSHANGHAI, July 22 (Reuters) - China shares rose on Thursday as gains in financials and materials firms outweighed losses in healthcare stocks, and as foreign investors extended net buying of A-shares through the Stock Connect scheme into a fourth consecutive day.\n\nAt the close, the Shanghai Composite index was up 0.34% at 3,574.73.\nThe blue-chip CSI300 index was up 0.15%, with its financial sector sub-index higher 1.12%, the CSI all share materials gaining 2.35% and the real estate index up 1.38%.\nThe healthcare sub-index slumped 3.64% after three days of strong gains.\nSentiment in the property sector was boosted after developer China Evergrande Group said it had solved legal disputes with China Guangfa Bank and that the two sides would deepen business cooperation, easing investor concerns that sparked a three-day sell-off.\nRefinitiv data showed foreign investors were net buyers of A-shares through the Northbound leg of the Stock Connect programme , the fourth straight day of net purchases.\nThe smaller Shenzhen index ended up 0.45% and the start-up board ChiNext Composite index was weaker by 0.438%.\nAround the region, MSCI’s Asia ex-Japan stock index was firmer by 1.21%, while Japan’s Nikkei index ended up 0.58%. ** At 07:22, the yuan was quoted at 6.4652 per U.S. dollar, 0.05% firmer than the previous close of 6.4685.\nSo far this year, the Shanghai stock index is up 2.9% and the CSI300 has fallen 1.1%, while China’s H-share index listed in Hong Kong is down 7%. Shanghai stocks have declined 0.46% this month.\n\n(Reporting by Shanghai Newsroom; editing by Vinay Dwivedi)","news_type":1},"isVote":1,"tweetType":1,"viewCount":381,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123129616,"gmtCreate":1624412720935,"gmtModify":1703835886825,"author":{"id":"3582529687850113","authorId":"3582529687850113","name":"CookInSuit","avatar":"https://static.tigerbbs.com/1a79bf61194a552988070fe312f320ed","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582529687850113","authorIdStr":"3582529687850113"},"themes":[],"htmlText":"How is the recovery trade over when there the world is still going through second and third&nbsp;wavesof Covid?","listText":"How is the recovery trade over when there the world is still going through second and third&nbsp;wavesof Covid?","text":"How is the recovery trade over when there the world is still going through second and third wavesof Covid?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123129616","repostId":"1168688117","repostType":4,"repost":{"id":"1168688117","pubTimestamp":1624404535,"share":"https://ttm.financial/m/news/1168688117?lang=&edition=fundamental","pubTime":"2021-06-23 07:28","market":"us","language":"en","title":"Barclays chief stock strategist says Covid recovery trade is over, go back into Big Tech","url":"https://stock-news.laohu8.com/highlight/detail?id=1168688117","media":"CNBC","summary":"The pandemic recovery trade has run its course, and now it’s time to get back into Big Tech stocks, ","content":"<div>\n<p>The pandemic recovery trade has run its course, and now it’s time to get back into Big Tech stocks, one market strategist told clients Tuesday.\n“We believe market leadership is likely to change from ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/22/stocks-barclays-strategist-says-go-back-into-big-tech.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Barclays chief stock strategist says Covid recovery trade is over, go back into Big Tech</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBarclays chief stock strategist says Covid recovery trade is over, go back into Big Tech\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 07:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/22/stocks-barclays-strategist-says-go-back-into-big-tech.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The pandemic recovery trade has run its course, and now it’s time to get back into Big Tech stocks, one market strategist told clients Tuesday.\n“We believe market leadership is likely to change from ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/22/stocks-barclays-strategist-says-go-back-into-big-tech.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞","AAPL":"苹果","AMZN":"亚马逊","GOOG":"谷歌","MSFT":"微软"},"source_url":"https://www.cnbc.com/2021/06/22/stocks-barclays-strategist-says-go-back-into-big-tech.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1168688117","content_text":"The pandemic recovery trade has run its course, and now it’s time to get back into Big Tech stocks, one market strategist told clients Tuesday.\n“We believe market leadership is likely to change from cyclical to secular growth stocks as the Covid recovery trade has mostly run its course. Secular growth stocks look favorably positioned to benefit from the digital transformation that got accelerated during Covid,” Barclays head of U.S. equity strategy Maneesh Deshpandesaid in a note.\nValue and cyclical stocks shone in 2021, as investors turned to names that perform well in a recovering economy. But the growth theme is back in vogue as investors worry that much of the pandemic rebound has already been priced into those recovery names.\n“Following positive news on the vaccine front in November 2020, as the path to a cyclical economic recovery in 2021 became clearer, there was a rotation that began away from stocks with positive exposure to COVID-19 and into stocks with negative exposure to it,” Deshpande said. “We think this rotation is now complete.”\nGrowth stocks are shares of companies that are expected to grow at a faster rate than the rest of the market. In particular, secular growth stocks follow a longer-term trend and are less influenced by the overall economy.\nAccording to Barclays, technology names are particularly well-positioned for the moment due to an acceleration of digital transformation during the pandemic. Tech stocks stand to benefit from the growth of e-commerce marketplaces, digital advertising, work-from-home technology and cloud infrastructure, the bank said.\nBarclays is bullish on FANMAG stocks — a group of mega-cap tech names including Facebook,Amazon,Netflix,Microsoft,Appleand Google-parentAlphabet. What’s more, the bank believes these Big Tech names are relatively cheap now after lagging earlier this year.\n“We prefer FANMAGs as their valuations have declined to 2019 [year-end] levels,” Deshpande said.\nMeanwhile, Barclays believes software stock valuations are currently expensive, so it prefers to stick with FANMAGs.\nOut of the tech giant names, Barclays likes Alphabet, Microsoft and Amazon in particular, as the bank expects these stocks to “hold on to their Covid market share gains and continue to benefit from the acceleration of digital transformation.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123122244,"gmtCreate":1624412935588,"gmtModify":1703835894164,"author":{"id":"3582529687850113","authorId":"3582529687850113","name":"CookInSuit","avatar":"https://static.tigerbbs.com/1a79bf61194a552988070fe312f320ed","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582529687850113","authorIdStr":"3582529687850113"},"themes":[],"htmlText":"Tesla has the halo effect. Wonder when Elon will wear out his halo..","listText":"Tesla has the halo effect. Wonder when Elon will wear out his halo..","text":"Tesla has the halo effect. Wonder when Elon will wear out his halo..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123122244","repostId":"2145599620","repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNOW":"Snowflake","TSLA":"特斯拉","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}